Logo

Diversa and Medarex Agree to Co-Develop Antibodies

Oct 17, 2003

NEW YORK, Oct. 17 (GenomeWeb News) - San Diego-based Diversa and Princeton, NJ-based Medarex yesterday announced they have entered into an R&D collaboration to develop and optimize antibodies to be used as drug targets.

 

Diversa plans to use its DirectEvolution technology, which generates randomized protein variants, to help engineer monoclonal antibodies. Medarex will bring its experience developing human monoclonal antibodies and its "extensive collaborative network" to the deal, Diversa president and CEO Jay Short said in a statement.

 

Breaking News
The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.